Ovid Therapeutics Maps Schizophrenia and Epilepsy Trial Milestones, With Cash Runway Into 2029
Ovid Therapeutics (NASDAQ:OVID) expects several clinical milestones over the next 12 months as it advances experimental treatments for schizophrenia and epilepsy, President and CEO Meg Alexander said at a company presentation. Alexander said the neurotherapeutics company has cash to fund operations into 2029. Its programs include OV4071, an oral drug targeting KCC2, and OV329, a […]
16 Nov 21:15 · The Cerbat Gem